Aspirin Does Not Need to Be Held for Routine Thoracentesis
Aspirin should be continued for thoracentesis in patients without additional bleeding risk factors, as it is not considered a contraindication and does not significantly increase bleeding risk for this low-risk procedure. 1
Evidence-Based Recommendation
The most recent 2025 critical care guidelines explicitly state that aspirin is not a contraindication to pleural drainage and may be continued 1. This represents the highest quality, most current guidance available and should direct clinical practice.
Key Supporting Evidence
Thoracentesis is classified as a low-risk bleeding procedure where aspirin continuation is safe 1. The guideline emphasizes that:
- Pleural puncture carries infrequent, mild bleeding that is easily controlled
- Aspirin does not significantly increase bleeding risk
- Discontinuation is unnecessary before performing drainage
- Hemothorax occurs in less than 1% of cases overall 1
Prospective research confirms this safety profile. A 2013 study of 312 thoracenteses found no hemothorax occurred in any patient, including those with bleeding risks 2. A 2021 retrospective study of 292 procedures showed zero bleeding events despite 83% of patients having uncorrected bleeding risk 3.
When Aspirin Might Be Held
The guidelines specify that temporary discontinuation may be necessary only when additional risk factors are present 1:
- Concomitant use of other hemostasis-modifying drugs (e.g., therapeutic anticoagulation plus aspirin)
- Congenital or acquired coagulopathy
- Comorbidities that independently increase bleeding risk
Contrast with Other Antiplatelet Agents
P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) require different management. While aspirin can be continued, P2Y12 inhibitors may need discontinuation in certain circumstances 1. The 2018 French guidelines recommend holding clopidogrel for 5 days, prasugrel for 7 days, and ticagrelor for 5 days before high-bleeding-risk procedures 4. However, for low-risk procedures like thoracentesis, even these agents may not require discontinuation in routine cases.
Clinical Pitfalls to Avoid
- Do not confuse thoracentesis with high-bleeding-risk procedures (like neurosurgery) where aspirin discontinuation for 5 days is recommended 4
- Do not routinely check or "correct" coagulation parameters before thoracentesis in aspirin users—the procedure can be safely performed without this
- Do not withhold aspirin to prevent bleeding when the patient requires it for cardiovascular protection—the thrombotic risk of discontinuation likely exceeds any minimal bleeding risk
Practical Algorithm
For a patient on aspirin requiring thoracentesis:
- Continue aspirin for routine thoracentesis
- Assess for additional bleeding risks: therapeutic anticoagulation, known coagulopathy, or multiple antiplatelet agents
- If no additional risks exist: proceed with thoracentesis without holding aspirin
- If additional risks present: consider case-by-case risk-benefit assessment 1
- Use ultrasound guidance: this further reduces complications 3
The evidence strongly supports aspirin continuation, avoiding unnecessary medication interruption that could increase thrombotic risk without meaningful bleeding benefit.